Insight, China's Pharmaceutical Industry

Haisco Pharma Secures NMPA Approval for HSK39297 – First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China

Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Takeda Secures World’s First NMPA Approval for Orexatone – Novel Oral OX2R Agonist for Type 1 Narcolepsy

Fineline Cube Jul 23, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026

Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607) announced a RMB 300 million (approximately...

Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026

TYK Medicines (HKG: 2410) and Qilu Pharmaceutical announced a comprehensive strategic partnership comprising three agreements:...

Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Fineline Cube Jul 22, 2026

Youcare Pharmaceutical (SHA: 688658) announced that its investigational compound YKYY033 has received clinical trial approval...

Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026

Trinomab Biotechnology Co., Ltd. (SHA: 688806) officially listed on the Science and Technology Innovation Board...

Company Legal / IP

Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market

Fineline Cube Jul 22, 2026

Novo Nordisk A/S (NYSE: NVO) announced it has filed a lawsuit against Eli Lilly and...

Company Drug

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Fineline Cube Jul 22, 2026

Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Gilead and Merck to Present Phase 3 ISLEND Trial Data for Once-Weekly Oral HIV Regimen at AIDS 2026 Conference

Fineline Cube Jul 22, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that...

Company Drug

Alebund Pharmaceuticals Initiates Global Phase IIb Trial of AP306, First-in-Class Oral Pan-Phosphate Transporter Inhibitor for Hyperphosphatemia

Fineline Cube Jul 22, 2026

Alebund Pharmaceuticals (HKG: 9637) announced that the first patient has been randomized and dosed in...

Others

Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline

Fineline Cube Jul 22, 2026

Nanjing Delova Biotech Co., Ltd. announced the completion of its Series C equity financing of...

Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026

Grand Pharmaceutical Group Limited (HKG: 0512) announced a comprehensive strategic commercialization partnership with Siemens Healthineers...

Company Drug

GSK Submits Bexsero Label Update to EMA for Single-Dose Booster in Adolescents and Adults Previously Vaccinated in Childhood

Fineline Cube Jul 21, 2026

GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted a...

Company Drug

Beijing Wantai’s RSV Vaccine Receives NMPA Clinical Trial Acceptance for Lower Respiratory Tract Disease Prevention

Fineline Cube Jul 21, 2026

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its clinical trial application...

Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026

Insilico Medicine (HKG: 3696) has signed a tripartite strategic cooperation agreement with Byterna Therapeutics, a...

Company Drug

Jacobio Pharmaceuticals’ JAB-8263 BET Inhibitor Proposed for NMPA’s Rare Disease “Caring Program” for Myelofibrosis Treatment

Fineline Cube Jul 21, 2026

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) announced that...

Company Drug

Eisai and Biogen Secure FDA Approval for LEQEMBI Subcutaneous Autoinjector for Early Alzheimer’s Disease Initiation

Fineline Cube Jul 21, 2026

Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) jointly announced that the U.S....

Company Deals

Samsung Biologics Bids $1.8 Billion for PolyPeptide Group to Enter High-Growth Peptide Therapeutics Market

Fineline Cube Jul 21, 2026

Samsung Biologics (KRX: 207940) announced an all-cash bid of 1.46 billion Swiss francs (USD 1.8...

Company Deals

Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients

Fineline Cube Jul 21, 2026

Akeso Biopharma (HKG: 9926) announced the signing of the Greater Bay Area Innovative Drug Charitable...

Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Fineline Cube Jul 21, 2026

The National Joint Procurement Office (NJPO) has issued the Notice on Corporate Affiliations for the...

Insight, China's Pharmaceutical Industry

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Haisco Pharma Secures NMPA Approval for HSK39297 – First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China

Takeda Secures World’s First NMPA Approval for Orexatone – Novel Oral OX2R Agonist for Type 1 Narcolepsy

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Gilead and Merck to Present Phase 3 ISLEND Trial Data for Once-Weekly Oral HIV Regimen at AIDS 2026 Conference

Alebund Pharmaceuticals Initiates Global Phase IIb Trial of AP306, First-in-Class Oral Pan-Phosphate Transporter Inhibitor for Hyperphosphatemia

Nanjing Delova Biotech Completes $83M Series C Financing to Advance Late-Stage Pain Management Pipeline

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

GSK Submits Bexsero Label Update to EMA for Single-Dose Booster in Adolescents and Adults Previously Vaccinated in Childhood

Beijing Wantai’s RSV Vaccine Receives NMPA Clinical Trial Acceptance for Lower Respiratory Tract Disease Prevention

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Jacobio Pharmaceuticals’ JAB-8263 BET Inhibitor Proposed for NMPA’s Rare Disease “Caring Program” for Myelofibrosis Treatment

Eisai and Biogen Secure FDA Approval for LEQEMBI Subcutaneous Autoinjector for Early Alzheimer’s Disease Initiation

Samsung Biologics Bids $1.8 Billion for PolyPeptide Group to Enter High-Growth Peptide Therapeutics Market

Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

You Missed

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors